This site is intended only for healthcare professionals residing in Singapore
Menu
Close
Menu
Close
Example of description text sitting alongside header
The diversity of non-small-cell lung cancer (NSCLC) has led to further subclassification of this disease beyond histological subtypes.1 Molecular analysis of genetic alterations in NSCLC, especially common in those with adenocarcinoma, has shown that lung cancer can also be divided by molecular subtypes.1 This has revolutionized targeted treatment options for patients and improved outcomes.2,3 The shift from histological to molecular subtypes is summarized in Figure 1, highlighting the diversity of molecular subtypes that exist within the patient population.4
Figure 1 - Histological and molecular subtypes of NSCLC.4
Embark on a journey to learn more about EGFR NSCLC through a wide range of resources. Access clinical data, patient brochures, treatment management materials, and webinars-on-demand.
Embark on a journey to learn more about ALK NSCLC through a wide range of resources. Access clinical data, patient brochures, treatment management materials, and webinars-on-demand.
Lung cancer refers to tumors originating in the lung parenchyma or within the bronchi.1 Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer, making up approximately 85% of lung cancers, and is defined as any type of epithelial lung cancer other than small cell lung cancer (SCLC).2,3
NSCLC can be further subdivided on the basis of histological features into several categories, the most common of which are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.4 Large cell carcinoma has been defined in the past as a tumor that lacks morphologic evidence of either glandular or squamous differentiation.5 Figure 1 shows some of the more common histological subtypes of tumors found in NSCLC.3
Lung cancer refers to tumors originating in the lung parenchyma or within the bronchi.1 Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer, making up approximately 85% of lung cancers, and is defined as any type of epithelial lung cancer other than small cell lung cancer (SCLC).2,3
NSCLC can be further subdivided on the basis of histological features into several categories, the most common of which are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.4 Large cell carcinoma has been defined in the past as a tumor that lacks morphologic evidence of either glandular or squamous differentiation.5 Figure 1 shows some of the more common histological subtypes of tumors found in NSCLC.3
Abbreviations
AKT1, AKT serine/threonine kinase 1; ALK, anaplastic lymphoma kinase; BRAF, v-raf murine sarcoma viral oncogene homolog B1; DDR2, discoidin domain receptor 2; EGFR, epidermal growth factor receptor; ERBB2, erb-b2 receptor tyrosine kinase 2; FGFR1, fibroblast growth factor receptor-1; HER2, human epidermal growth factor receptor 2; KRAS, Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; MEK1, MAPK kinase 1; MET, mesenchymal‐to‐epithelial transition; NRAS, neuroblastoma RAS viral (v-ras) oncogene homolog; NSCLC, non-small-cell lung cancer; NTRK1, neurotrophic tyrosine kinase 1; PIK3CA, phosphoinositide-3-kinase, catalytic, alpha polypeptide; PTEN, phosphatase and tensin homolog deleted on chromosome 10; RET, rearranged during transfection; ROS1, c-ros oncogene 1; WT, wild-type.
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
The information provided in this site is intended only for Healthcare Professionals in Singapore. The products discussed herein may have different product labelling in different countries. Pfizer Pte Ltd, Singapore is a subsidiary of Pfizer Inc, a pharmaceutical company committed to helping people improve their health by discovering and developing medicines.
Copyright © 2023 Pfizer Limited. All rights reserved.